OncoMatch/Clinical Trials/NCT04280822
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Is NCT04280822 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Neoadjuvant immunochemotherapy for esophageal cancer.
Treatment: Neoadjuvant immunochemotherapy — The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1N1-3M0, T2-3N0-3M0 (8th Union for International Cancer Control, UICC-TNM)
Stage (T1N1-3 or T2-3N0-3 M0), (8th Union for International Cancer Control, UICC-TNM)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anticancer therapy
Patients must not have received any prior anticancer therapy of esophageal carcinoma.
Lab requirements
Blood counts
white blood cells count ≥4.0×10^9/L, neutrophil ≥1.5×10^9/L, platelets ≥100.0×10^9/L, hemoglobin ≥90g/L
Kidney function
normal functions of kidney, endogenous creatinine clearance rate(CRE)≤1.5N
Liver function
normal functions of liver, total bilirubin（TBIL）≤1.5N, aspartate aminotransferase (AST)≤2.5N, alanine aminotransferase(ALT)≤2.5N
Absolute white blood cells count ≥4.0×10^9/L, neutrophil ≥1.5×10^9/L, platelets ≥100.0×10^9/L, hemoglobin ≥90g/L, and normal functions of liver and kidney, total bilirubin（TBIL）≤1.5N, aspartate aminotransferase (AST)≤2.5N, alanine aminotransferase(ALT)≤2.5N, prothrombin time(PT)≤1.5N, and activated partial thromboplastin time(APTT) is in normal range, endogenous creatinine clearance rate(CRE)≤1.5N.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04280822 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T1N1-3M0 or T2-3N0-3M0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages